Alemtuzumab

BNF:
8.2.3
Status:
Red
Decision Date:
June 2014
 

Comments

RED

  • NICE TA312: for treating highly active relapsing remitting multiple sclerosis.  NHSE commissioned.  (Decision date - June 2014).


Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app